

Nogalska A., Engel W.K., McFerrin J., Kokame K., Komano H., and Askanas V.	Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers	J. Neurochem.	96	1491-1499	2006
Araki W., Saito S., Takahashi-Sasaki N., Shiraishi H., Komano H., and Murayama K.S.	Characterization of APH-1 mutants with a disrupted transmembrane GxxxG motif	J. Mol. Neurosci.	印刷中		2006
Hashimoto M, Nitta A, Fukumitsu H, Nomoto H, Shen L, Furukawa S.	Involvement of glial cell line-derived neurotrophic factor in activation processes of rodent macrophages.	J Neurosci Res.	5;79	476-487	2005
Miyoshi M, Nadai M, Nitta A, Ueyama J, Shimizu A, Takagi K, Nabeshima T, Takagi K, Saito K, Hasegawa T.	Role of tumor necrosis factor-alpha in down-regulation of hepatic cytochrome P450 and P-glycoprotein by endotoxin.	Eur J Pharmacol.	10;507	229-237	2005
Hashimoto M, Nitta A, Fukumitsu H, Nomoto H, Shen L, Furukawa S.	Inflammation-induced GDNF improves locomotor function after spinal cord injury.	Neuroreport	8;16	99-102	2005
Ishikawa K., Nitta A., Mizoguchi H., Mohri A., Murai R., Miyamoto Y., Noda Y., Kitaichi K., Yamada K., and Nabeshima T.	Effects of single and repeated administration of methamphetamine or morphine on neuroglycan C gene expression in the rat brain	Int J Neuropsychopharmacol	7	1-9	2005
Mizuno T., Kuno R., Nitta A., Nabeshima T., Zhang G., Kawanokuchi J., Wang J., Jin S., Takeuchi H., and Suzumura A.	Protective effects of nigerin against neuronal cell death induced by activated microglia and astrocytes.	Brain Res.	1066	75-85	2005
Enomoto T., Noda Y., Mouri A., Shin E.J., Wang D., Murai R., Hotta K., Furukawa H., Nitta A., Kim H.C., and Nabeshima T.	Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine.	Mol Pharmacol.	68	1765-1744	2005
Yan Y., Nitta A., Mizoguchi H., Yamada K., and Nabeshima T.,	Relapse of methamphetamine-seeking behavior in C57BL/6J mice demonstrated by a reinstatement procedure involving intravenous	Behav Brain Res.	15	145-175	2005

	us self-administration.				
Cen X., Nitta A., Ohya S., Zhao Y., Ozawa N., Mouri A., Ibi D., Wang L., Suzuki M., Saito K., Ito Y., Kawagoe T., Noda Y., Ito Y., Furukawa S., and Nabeshima T.,	An analogue of dipeptide-like structure of FK506 increases GDNF expression through CREB activated by Hsp90/Akt signaling pathway.	J. Neurosci.	in press		

雑誌 2004年度

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Naoui M, Maruyama W, Nagy GM	Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: Occurrence, metabolism and function in human brains.	NeuroToxicology	25	193-204	2004
Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoui M.	N-Propargyl-1(R)-aminoglutathion, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.	Neurochemistry International	44	393-400	2004
Maruyama W, Yi H, Takahashi T, Shimazu S, Ohde H, Yoneda K, Iwasaki K, Naoui M. (2004)	Neuroprotective function of R-(-)-(benzofuran-2-yl)-2-propylamino-pentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)-salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells.	Life Sciences	75	107-117	2004
Shamoto-Nagai M, Maruyama W, Akao Y, Osawa T, Tribl F, Gerlach M, Zucca FA, Zecca L, Riederer P, Naoui M.	Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells	Journal of Neural Transmission	111	1253-1265	2004
Akao Y, Seki N, Nakagawa Y, Yi H, Matsumoto K, Ito Y, Ito K, Funahashi M, Maruyama W, Naoui M, Nozawa Y	A highly bioactive ligno-phenol derivative from bamboo lignin exhibits a potent activity to suppress apoptosis induced by oxidative stress in human neuroblastoma SH-SY5Y cells.	Bioorganic & Medicinal Chemistry	12	4791-4801	2004
Trisomboon H., Malaivijitnond, S., Suzuki J., Hamada Y., Watanabe G., Taya K.	Long-term treatment of <i>Pueraria mirifica</i> phytoestrogens on parathyroid hormone and calcium levels in aged menopausal cynomolgus monkeys.	J. Reprod. & Development	50	639-645	2004

Tsuruta, F., Sunayama, J., Mori, Y., Hattori S., Shimizu, S., Tsujimoto, T., Yoshioka, K. and Gotoh, Y.	JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins.	EMBO J.	23	1889-1899	2004
Hitomi, J., Katayama, T., Eguchi, Y., Kudo, T., Taniguchi, M., Koyama, Y., Manabe, T., Yamagishi, S., Bando, Y., Imaizumi, K., Tsujimoto, Y. and Tohyama M.	Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Ab-induced cell death.	J. Cell Biol.	165	347-356	2004
Zhang, L., Shimizu, S., Sakamaki, K., Yonehara, S., and Tsujimoto, Y.	A caspase-8-independent signalling pathway activated by Fas ligation leads to exposure of Bax N-terminus.	J. Biol. Chem.	279	33865-33874	2004
Lee, J.-H., Jeon M.-H., Seo Y.-J., Lee, Y.-J., Ko J. H., Tsujimoto, Y. and Lee, J.-H.	CA repeats in the 3' UTR of bcl-2 mRNA mediate constitutive decay of bcl-2 mRNA.	J. Biol. Chem.	289	42758-42764	2004
Shigeomi Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, K., Arakawa-Kobayashi, S., Thompson, C. B., and Tsujimoto, Y.	A role of Bcl-2 family of proteins in non-apoptotic programmed cell death dependent on autophagy genes	Nature Cell Biol.	6	1221-1228	2004
Sugioka, R., Shimizu, S. and Tsujimoto, Y.	Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis.	J. Biol. Chem.	279	52726-52734	2004
Kanamori, D., Okamura, T., Yamamoto, H., Shimizu, S., Tsujimoto, Y., and Ueyama, N.	Structure of the small-molecule Bcl-2 inhibitor (BH3I-2) and its related simple model in protonated and deprotonated forms.	Bull Chem. Soc. Jap.	77	2057-2064	2004
Shiraishi H., Sai X., Wang H.-	PEN-2 enhances g-cleavage after the formation of	Journal of Neurochemistry	90	1402-1413	2004

Q., Maeda Y., Kurohara Y., Nishimura M., Yanagisawa K., and Komano H.	Presenilin heterodimer				
Nagai T, Yamada K, Yoshimura M, Ishikawa K, Miyamoto Y, Hashimoto K, Noda Y, Nitta A, Nabeshima T.	The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release.	Proc Natl Acad Sci USA	9;101(10)	3650-3655.	2004
Mizoguchi H, Yamada K, Mizuno M, Mizuno T, Nitta A, Noda Y, Nabeshima T.	Regulations of methamphetamine reward by extracellular signal-regulated kinase 1/2/ets-like gene-1 signaling pathway via the activation of dopamine receptors.	Mol Pharmacol.	65(5)	1293-1301	2004
Hamdy MM, Noda Y, Miyazaki M, Mamiya T, Nozaki A, Nitta A, Sayed M, Assi AA, Gomma A, Nabeshima T.	Molecular mechanisms in dizocilpine-induced attenuation of development of morphine dependence: an association with cortical Ca <sup>2+</sup> /calmodulin-dependent signal cascade.	Behav Brain Res.	152(2)	263-270	2004
Kinukawa H, Jikou T, Nitta A, Furukawa Y, Hashimoto M, Fukumitsu H, Nomoto H, Furukawa S.	Cyclic AMP/protein kinase a signal attenuates Ca <sup>2+</sup> -induced fibroblast growth factor-1 synthesis in rat cortical neurons.	J Neurosci Res.	15;77(4)	487-497	2004
Nitta A, Nishioka H, Fukumitsu H, Furukawa Y, Sugiura H, Shen L, Furukawa S.	Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis.	J Neurosci Res.	15;78(2)	250-258	2004
直井信、丸山和佳子	神経毒によるパーキンソン病モデル：細胞死機序の解明と神経保護薬の開発、	脳の科学 増刊「パーキンソン病のすべて」	26	157-164	2004
丸山和佳子、直井信	神経保護薬	内科	93	709-712	2004
丸山和佳子、直井信	Parkinson病の発症機序-Update,	医学のあゆみ	208	477-481	2004
丸山和佳子、永井雅代、直井信	弧発性パーキンソン病におけるドパミン神経選択的細胞死の機序：酸化ストレスとプロテアソーム機能障害を結ぶもの	Progress in Medicine	24	3054-3058	2004

寺尾啓治、 小山高正、 鈴木樹理	実験用霊長類の心理的ストレスを評価する免疫学的指標と飼育環境のエンリッチメント評価	実験動物技術	39	97-104	2004
------------------------	---	--------	----	--------	------

T. L. Török & I. Klebovich (eds.)

Monoamine Oxidase  
inhibitors and their role  
in neurotransmission  
(drug development)

Medicina Publishing House Co. • Budapest, 2004

MONOAMINE OXIDASE  
AND THE INHIBITORS:  
INVOLVEMENT IN CELL DEATH  
AND SURVIVAL OF NEURONS

*Makoto Naoi<sup>1,\*</sup> and Wakako Maruyama<sup>2</sup>*

- 1: Department of Neurosciences, Gifu International Institute  
of Biotechnology, Kakamigahara, Gifu 504-0838, Japan,  
2: Department of Basic Gerontology, National Institute for Longevity  
Sciences, Obu, Aichi 474-8522, Japan,

*Corresponding author: Department of Neurosciences, Gifu International  
Institute of Biotechnology, 1-1 Naka-fudogaoka, Kakamigahara,  
Gifu 504-0838, Japan  
Tel: +81-583-71-4646; fax: +81-583-71-4412.  
E-mail address: mnaoi@giib.or.jp (M. Naoi)*



## Abstract

In human brain, monoamine oxidase plays a major role in regulation of monoamine neurotransmitter level by the oxidative deamination. However, its occurrence in the outer membrane of mitochondria suggests that monoamine oxidase may be involved in the decision of cell death or survival of neurons, since the mitochondria are now considered to mediate death signal in neurodegenerative disorders, such as Parkinson's disease. Recently we examined the role of type A monoamine oxidase in apoptosis induced by an endogenous neurotoxin, *N*-methyl(*R*)salsolinol. The (*R*)enantiomers of salsolinol [1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline] derivatives were found to inhibit type A monoamine oxidase in competition to the substrates. In addition, the selective neurotoxicity of the (*R*)enantiomer of *N*-methylated salsolinol to dopamine neurons was confirmed by preparation of an animal model of Parkinson's disease in rats. *N*-Methyl(*R*)salsolinol enantio-selectively binds to the outer membrane of mitochondria, induces mitochondrial permeability transition in isolated mitochondria, and causes apoptosis in cultured dopaminergic neurons. These results suggest the occurrence of the target protein with stereo-structure similar to the binding site of type A monoamine oxidase. On the other hand, among inhibitors of type B monoamine oxidase some propargylamine derivatives protect neuronal cells from apoptosis by stabilizing mitochondrial membrane potential and inhibiting the activation of cell death signal transduction. The anti-apoptotic function of the propargylamines depends on their stereo-chemical structure; the (*R*)-enantiomers protect neurons more markedly than the (*S*)-enantiomers, suggesting the presence of the distinct binding site in mitochondria. These results strongly suggest that monoamine oxidase or structurally related proteins may play a major role in the regulation of cell death and survival in neurodegenerative disorders.

## Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder and its major pathological feature is the cell death of dopamine neurons in the substantia nigra projecting to the putamen and caudate of the brain. There are numerous contradicting results concerning the type of cell death in PD, but signs of activated apoptotic process were detected in the nigro-striatum of parkinsonian brains [1, 2]. Mitochondria have been considered to contribute to the development and progression of PD

either through the dysfunction of the complex I with subsequent reduced ATP synthesis and/or increased oxidative stress [3, 4]. However, recently direct involvement of mitochondria in neuronal apoptosis has been indicated [5, 6]. Various insults including oxidative stress, metabolic compromise and neurotoxins, induce opening of mitochondrial permeability transition (PT) pore with loss of membrane potential,  $\Delta\Psi_m$ . The exact composition of PT remains to be characterized, but it is composed of voltage-dependent anion channel, adenine nucleotide translocator, cyclophilin, creatine kinase, porin and hexokinase [7, 8]. Mitochondrial PT pore is regulated by bcl-2 family protein, either in suppressive (Bcl-2, Bcl-xL), or promoting way (Bax, Bad) [9, 10]. PT induces release of cytochrome c, apoptosis inducing factor and  $Ca^{2+}$  from mitochondria to cytoplasm, which promotes cleavage and activation of procaspase 9, followed by that of effector caspases, procaspase-3 and procaspase-7. Finally nuclear DNA undergoes strand cleavage and condensation.

The type A and B of monoamine oxidase [monoamine: oxygen oxidoreductase (deaminating), EC. 1.4.3.4, MAO] are located in mitochondrial outer membrane of neuronal, glial and other cells. MAO catalyzes the oxidative deamination of monoamine neurotransmitters, dopamine, norepinephrine and serotonin, and regulates their levels in the brain, indicating the important role in several neurological and psychiatric disorders [11, 12]. Oxidation of dopamine by MAO produces a cytotoxic reactive oxygen species (ROS), hydrogen peroxide, and dopaquinone, which cause inhibition of mitochondrial respiration, lipid peroxidation and finally cell death in PD [13, 14]. In addition, MAO, especially type B, oxidizes a protoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into an active toxin, 1-methyl-4-phenylpyridinium ion (MPP<sup>+</sup>), resulting in cell death of dopamine neurons in humans [15]. Inhibitors of MAO-B prevented MPTP-induced neuronal decline in primate [16], and delayed the progress of PD in humans [17, 18]. However, recent results from various points of view suggest that MAO may be involved directly in apoptotic process. In apoptosis induced by nerve growth factor withdrawal in PC12 cells, MAO expression was increased and identified as a potential target of pro-apoptotic signaling of p38 mitogen-activated protein (MAP) kinase [19]. Figure 1 shows the hitherto proposed role of MAO in the neuronal cell death in PD. Inhibition of oxidative phosphorylation by ROS and cytotoxic MPP<sup>+</sup> and quinone, induces necrosis, whereas mitochondrial PT leads to apoptosis through activation of death cascade.


We found that (-)-deprenyl and related MAO-B inhibitors, including rasagiline [*N*-propargyl-1(*R*)-aminoindan], *N*-(2-heptyl)-*N*-methylpropargylamine [(*R*)-2-HMP] and other propargylamines, enantio-selec-

tively protect dopamine neurons against apoptosis induced by neurotoxins, 6-hydroxydopamine (6-OHDA) [20], *N*-methyl(*R*)salsolinol [1(*R*),2(*N*)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydropyridine, *NM(R)Sal*] [21–24], and nitric oxide and peroxynitrite [25]. These results suggest that compounds with affinity to the MAO-A binding site may be cytotoxic, whereas those to MAO-B may be related to neuroprotection.

Can MAO-A and MAO-B be involved in the decision of cell death either in promoting or inhibiting way though regulating mitochondrial death machinery? To prove our hypothesis, we examined the role of MAO in apoptosis induced by *NM(R)Sal*, a MAO-A inhibitor, and neuroprotection by propargylamine MAO-B inhibitors. This review summarizes our recent results in concern to new function of MAO regulating cell death in neurodegenerative disorders.

Fig. 1

**Involvement of MAO in cell death in Parkinson's disease.** In neurons MAO oxidizes dopamine to produce hydrogen peroxide and autooxidation to dopaquinone, which inhibit mitochondrial complex I directly or indirectly through oxidative modification and lipid peroxidation. In glial cells MAO-B oxidizes MPTP to MPP<sup>+</sup>, which is taken up by dopamine transport system in neurons, where it inhibits complex I. Mitochondrial dysfunction increases superoxide, which reacts with nitric oxide to produce peroxynitrite. Peroxynitrite damages nuclear DNA directly. (-)Deprenyl prevents oxidation of MPTP to MPP<sup>+</sup>, whereas propargylamines suppress opening of PT pore.



## Endogenous isoquinolines as inhibitors of MAO-A

Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, Sal) was for the first time detected in urine of parkinsonian patients treated with L-DOPA [26]. In human tissues three classes of monoamine-derived alkaloids have been reported; dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines (catechol TIQs), and  $\beta$ -phenethylamine-derived TIQs and indolamine-derived  $\beta$ -carbolines [27, 28]. The non-enzymatic Pictet-Spengler reaction produces Sal derivatives from dopamine with aldehydes or keto-acids. However, the predominant occurrence of the (*R*) enantiomers of Sal was confirmed in human urine [29, 30] and the brain [31]. It suggests the enzymatic synthesis of Sal *in situ*, and the enzymes for the biosynthesis were isolated from human brains. (*R*)Salsolinol synthase catalyzes the enantio-specific synthesis of (*R*)salsolinol from dopamine and acetaldehyde [32], and (*R*)salsolinol *N*-methyltransferase synthesizes *NM*(*R*)Sal [33], which is further oxidized into 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion [DMDHIQ<sup>+</sup>] by non-enzymatic and enzymatic oxidation [34]. The step-wise reactions, *N*-methylation and oxidation, induce the specified distribution of *NM*(*R*)Sal and DMDHIQ<sup>+</sup> in the nigro-striatum of human brain [35].

Sal derivatives were relatively weak, but selective and competitive inhibitors of MAO-A [36, 37], and the (*R*)-enantiomers are more potent than the (*S*)-enantiomers [38]. The structure-activity relationship of Sal as MAO inhibitors was reported in details previously [39, 40]. The effects of naturally occurring catechol isoquinolines on activities of MAO-A and B were examined using mitochondria prepared from human brain synaptosomes, and the results are summarized in Table 1. The (*R*)-enantiomers of Sal and *NM*Sal inhibited MAO-A more potent than the (*S*) enantiomers, and the inhibition was competitive to the substrate, whereas that of MAO-B was noncompetitive, as shown in Figure 2 [41]. The presence of hydroxyl groups at 6 and 7 position and substitution of a hydrogen group at the first position with a methyl or dihydroxybenzyl group is required for the inhibition, whereas the presence of a carboxy group at this position depletes the inhibitory activity. The oxidized DMDHIQ<sup>+</sup> is the most potent inhibitor of MAO-A [42].

### The enantio-selective neurotoxicity of *N*-methyl(*R*)salsolinol

The induction of parkinsonism in humans by MPTP [43] suggests that endogenous and xenobiotic neurotoxins may be pathogenic factors of PD.

Table 1  
The  $K_i$  value of salsolinol derivatives to type A and B MAO in human brain synaptosomes

Salsolinol derivatives	K <sub>i</sub> values (μM) for monoamine oxidase	
	Type A	Type B
(R)Salsolinol	37.9	68.3
(S)Salsolinol	149.5	149.5
2(N)-Methyl(R)salsolinol	36.1	433.3
2(N)-Methyl(S)salsolinol	81.3	No inhibition
Norsalsolinol	No inhibition	No inhibition
2(N)-Methynorsalsolinol	61.4	289
1,2(N)-Dehydrosalsolinol	322.3	No inhibition
1-Carboxyl-(R)salsolinol	421.3	No inhibition
1,2(N)-DM-6,7-DHIQ <sup>+</sup> *	9.21	No inhibition
2(N)-M-6,7-DHIQ <sup>+</sup> **	44.4	No inhibition
2(N)-M-1-carboxyl(R)salsolinol***	No inhibition	No inhibition

\*, \*\* 1,2(N)-Dimethyl- and 2(N)-methyl 6,7-dihydroxyisoquinolinium ion


\*\*\* 2(N)-Methyl-1-carboxyl(R)salsolinol

The biosynthesis of Sal derivatives from dopamine and acetaldehyde suggests their involvement in pathological features of dopamine- or alcohol-related neurodegenerative disorders, such as PD and alcoholism. We examined the cytotoxicity of Sal derivatives to nigro-striatal dopamine neurons by the injection in the rat brain striatum [44]. NM(R)Sal induced parkinsonism in rats with reduction of dopamine levels and selective degeneration of dopamine neurons in the substantia nigra, proving this rat model to be adequate as a PD model. On the other hand, NM(S)Sal and other Sal derivatives did not cause any biochemical, behavioral and histo-pathological changes in rats. Involvement of NM(R)Sal in the pathogenesis of PD was suggested by significantly high level of N(R)Sal in the cerebrospinal fluid [45], and of (R)Sal N-methyltransferase activity in lymphocytes from parkinsonian patients [46].

NM(R)Sal induced apoptosis in dopamine neurons and the mechanism of cell death was studied using human dopaminergic neuroblastoma SH-SY5Y cells [22–24, 47, 48] Among catechol isoquinolines, NM(R)Sal

Fig. 2

The effects of Sal derivatives on MAO-A and B activity. MAO-A and B were prepared from human brain synaptosomes. A: MAO-A activity. B: MAO-B activity. The reciprocal of the reaction velocity was plotted against that of the substrate, kynuramine, concentration. I: Control, II; +100  $\mu$ M (*R*)Sal, III; *NM(R)*Sal, IV; DMDHIQ<sup>+</sup>.



was the most potent to induce DNA damage, whereas the (*S*) enantiomer, Sal and DMDHIQ<sup>+</sup> were less apoptogenic, as summarized in Table 2. Figure 3 shows that *NM(R)*Sal induced cell death in SH-SY5Y cells, and most of dead cells were apoptotic, as shown by condensed and fragmented nuclei stained with Hoechst 33342. The intracellular mechanism underlying the apoptosis induced by *NM(R)*Sal was clarified as shown in Figure 4. The neurotoxin induced mitochondrial PT with collapse in membrane potential,  $\Delta\Psi_m$ , followed by release of cytochrome C, activation of caspase 3, nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase [D-glyceraldehyde-3-phosphate: NAD<sup>+</sup> oxidoreductase (phosphorylating), EC1.2.1.12, GAPDH], and finally condensation and fragmentation of nucleosomal DNA. Only the (*R*)-enantiomer of *NMSal* induced  $\Delta\Psi_m$  decline in SH-SY5Y cells, and the (*S*)-enantiomer did not [22], as shown in Figure 5. The enantio-specificity of the (*R*)-enantiomer was further confirmed by induction of  $\Delta\Psi_m$  decline and swelling in isolated mitochondria [24].

These results suggest the presence of proteins in mitochondrial outer membrane, which distinguish the three-dimensional structure of the (*R*)-configuration of *NM(R)*Sal and induce mitochondrial PT.

Table 2  
Cytotoxicity of salsolinol derivatives to SH-SY5Y cells

Salsolinol derivatives	Apoptotic cells (% of the total cells)	Necrotic cells
Control	4.86 ± 4.34	1.21 ± 1.68
( <i>R</i> )Salsolinol	9.55 ± 2.26	1.70 ± 1.41
( <i>S</i> )Salsolinol	10.71 ± 4.54	1.33 ± 0.68
<i>N</i> -Methyl( <i>R</i> )salsolinol	100 <sup>#</sup>	0
<i>N</i> -Methyl( <i>R</i> )salsolinol <sup>#</sup>	26.73 ± 4.57 <sup>#</sup>	0.85 ± 0.68
<i>N</i> -Methyl( <i>S</i> )salsolinol	10.9 ± 3.04	0.28 ± 0.44
DMDHIQ <sup>*</sup>	28.02 ± 9.09 <sup>#</sup>	1.58 ± 1.8
( <i>R</i> )-1-Carboxy-Sal	3.73 ± 1.75	1.08 ± 1.10
( <i>S</i> )-1-Carboxy-Sal	5.72 ± 2.41	1.01 ± 0.78
Norsalsolinol	34.06 ± 5.05 <sup>#</sup>	1.63 ± 1.68
<i>N</i> -Methylnorsalsolinol	8.87 ± 0.73	0.13 ± 0.32

The apoptotic and necrotic cells were classified by morphological observation after staining with Hoechst 33346.

The concentrations used were 500 μM, except <sup>\*</sup>, 250 μM.

The number represents mean ± SD of three independent experiments.

<sup>#</sup> Difference from control is statistically significant,  $p < 0.01$ .


## Neuroprotection by propargylamine MAO-B inhibitors

Recently, "neuroprotective" therapy has been proposed to attenuate the progressive decline of distinct neurons in neurodegenerative disorders [49, 50]. Candidates of neuroprotective agents are neurotrophic factors, anti-oxidant, radical scavengers, dopamine agonists, inhibitors of nitric oxide synthase and immuno-suppressors. A series of propargylamine derivatives related to (-)-deprenyl have been reported to prevent cell death of dopamine neurons in animal and cellular models of PD [51-53]. The intracellular mechanism underlying neuroprotection by propargylamines was studied using a cellular model of apoptosis induced by *NM(R)Sal* in SH-SY5Y cells. Figure 6 shows the chemical structure of propargylamines, whose anti-apoptotic capacity was confirmed.

Propargylamines protect the cells from apoptosis induced by the toxin, and the anti-apoptotic potency depends on the enantiomeric properties; the (*R*)-enantiomers were more potent than the (*S*)-enantiomers.

Fig. 3

**NM(R)Sal induced apoptotic nuclear damage in SH-SY5Y cells.** The cells were treated with 500  $\mu$ M of NM(R)Sal for 18 hours. Propidium iodide (PI) stained almost all the NM(R)Sal-treated cells. The nuclei were stained with a membrane-permeable dye, Hoechst 33342. Most of the nuclei in the toxin-treated cells were condensed and fragmented, as typical markers for apoptosis.



mers, as summarized in Table 3. Rasagiline and (*R*)-2-HMP prevent the  $M_{PT}$  decline in SH-SY5Y cells [21, 22] and in mitochondria prepared from rat liver (Figure 4) [24]. Rasagiline prevents the activation of following apoptotic signals: release of cytochrome c, activation of caspase 3, nuclear translocation of GAPDH and finally fragmentation of nuclear DNA, indicating that prevention of PT is primary for the anti-apoptotic function. The study on structure-activity relationship of propargylamines reveals that a propargyl residue is absolutely required for the stabilization of ADYm and the (*R*)-enantiomers are more potent to suppress the PT than the (*S*)-enantiomers [55].


These results suggest that a propargylamine residue should bind to protein closely associated with PT pore in the mitochondrial outer membrane. The detailed mechanism remains to be elucidated, but anti-apoptotic Bcl-2 protein seems to mediate the pro-survival function.



Fig. 4

**Apoptotic cascade induced by NM(R)Sal.**

**NM(R)Sal induces mitochondrial PT in isolated mitochondria, as shown by swelling, then cytochrome C is released into cytoplasm in SH-SY5Y cells. Caspase 3 is activated, as shown by appearance of the active form with 17 kDa. Simultaneously GAPDH is translocated into nuclei, as detected with anti-GAPDH antibody. Finally nuclear DNA is cleaved to fragments, as shown by the ladder formation.**



**The involvement of MAO in the apoptotic process: some evidences supporting our hypothesis**

Recent several papers suggest the involvement of MAO in apoptosis, but most of the results were indirect: MAO-A mRNA increased during apoptosis induced by NGF-withdrawal in PC12 cells [19], and MAO-B gene was induced in apoptosis by Galectin-7 (PIG1) in HeLa and DLD-1 cells [56]. We also found that rasagiline treatment increased MAO-A mRNA level in SH-SY5Y cells by two-folds. Previous papers interpreted the induction of MAO mRNA as increased of ROS produced by

Table 3  
Anti-apoptotic activity of propargylamines

Compounds	Concentration required for the effect
(-)-Deprenyl (selegiline)	1 $\mu$ M-100 nM
(+)-Deprenyl	10 $\mu$ M
(-)-Desmethyldeprenyl	10-1 nM
(R)(+)-N-Propargyl-1-aminoindan (Rasagiline)	10-1 nM
(S)(-)-N-Propargyl-1-aminoindan (TV 1022)	1 $\mu$ M-100 nM
Aminoindane	Not active
(R)-N-(2-Heptyl)-N-methylpropargylamine	1 $\mu$ M-100 nM
(S)-N-(2-Heptyl)-N-methylpropargylamine	10 $\mu$ M
(R)-3-(2-Heptylamine)-N-methylpropionic acid	Not active

SH-SY5Y cells were incubated with various concentrations of propargylamines for 20 min, then treated with 500  $\mu$ M NM(R)Sal for 3 hours. Apoptotic cell death was quantitatively determined by "comet" assay, and the concentration required for the complete protection of the cells from apoptosis was obtained.

enzymatic oxidation of dopamine, as in the case with suppression of apoptosis by MAO-inhibitors [57, 58].

However, the results represented here strongly suggest that MAO may directly intervene apoptotic machinery, as shown by the enantio-selective induction of PT by NM(R)Sal in isolated mitochondria and the cells. Recently we found that serotonin, a substrate of MAO-A, suppresses the  $\Delta\Psi_m$  decline of isolated mitochondria induced by NM(R)Sal in a competitive way. On the other hand, clorgyline, an irreversible inhibitor of MAO-A, induced PT and apoptosis in SH-SY5Y cells. These results suggest that the binding site of neurotoxin and MAO-A substrates may be a common protein with binding site similar to that of MAO-A in mitochondria. MAO-A is detected predominantly in the substantia nigra, locus coeruleus, striatum and other regions containing catecholamine neurons, suggesting possible involvement of MAO-A in dopaminergic cell death in PD. On the other hand, the binding of anti-apoptotic propargylamines is not limited to MAO-B but also MAO-A, which may be relevant with the fact that MAO inhibitors has two different binding affinities; highly selective binding at nM order and low selective one at  $\mu$ M order.

Fig. 5

**Changes of NM in the cells treated with NMSal.**  
**SH-SY5Y cells were incubated in the absence or presence of 250 nM of NM(R)Sal or NM(S)Sal for 3 hours. Phase-contrast microscopy and the fluorescence microscopy after staining with JC-1. Red fluorescence represents J-aggregates inside intact mitochondria. The fluorescence decreased in the cells treated with NM(R)Sal without morphological change shown by phase-contrast microscopy. J-Aggregate fluorescence did not change in the cells treated with NM(S)Sal.**





Fig. 6


**Chemical structure of propargylamines with anti-apoptotic capacity.**



(S)-Deprenyl (selegiline)



(R)-Propargyl-1(R)-aminocindolin  
(Rasagiline)



N-(2-Heptyl)-N-methylpropargylamine  
(LHMP)

In this review, we propose our hypothesis about a novel function of MAO-A and MAO-B, as regulators of cell death and survival. We are now working further on this subject and we hope to be able to present more concrete evidences in near future.

## Acknowledgement

This work was supported by grants from the following programs: Grants-in-Aids on Grants-in-Aid for Scientific Research (C) (W. M.) from the Ministry of Education, Culture, Sports and Science and Technology, Japan; Grant-in-Aid for Scientific Research on Priority Areas (C) from Japan Society for the Promotion of Science (W. M.); Grants for Longevity Sciences (W. M.), Grants for Clinical Research of Evidence-Based Medicine (W. M., M. N.) from the Ministry of Health, Labour and Welfare, Japan.

## References

1. Hartmann, A., Hunot, S., Michel, P.P., Muriel, M.P., Vyas, S., Faucheux, B.A., Mouatt-Prigent, A., Turmel, H., Srinivasan, A., Ruberg, M., Evan, G.I., Agid, Y., Hirsch, E.C.: Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. *Proc Natl Acad Sci USA* 2000, 97, 2875-2880.
2. Tatton, N.A.: Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease, *Exp Neurol* 2000, 166, 29-43.
3. Schapira, A.H.V., Cooper, J.M., Dexter, D., Jenner, P., Clark, J.B., Marsden, C.D.: Mitochondria complex I deficiency in Parkinson's disease. *Lancet* I, 1989, 1269.
4. Mizuno, Y., Ikebe, S., Hattori, N., Nakagawa-Hattori, Y., Mochizuki, H., Tanaka, M., Ozawa, T.: Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. *Biochim Biophys Acta* 1995, 1271, 265-274.
5. Susin, S.A., Zamzami, N., Kroemer, G.: Mitochondria as regulators of apoptosis: doubt no more. *Biochim Biophys Acta* 1998, 1366, 151-165.
6. Naoi, M., Maruyama, W., Akao, Y., Yi, H.: Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, *N*-methyl(*R*)-salsolinol, and neuro-protection by propargylamines. *J Neural Transm* 2002, 109, 607-621.
7. Zoratti, M., Szabo I.: The mitochondrial permeability transition. *Biochim Biophys Acta* 1995, 1241, 139-176.
8. Beutner, G., Rude, A., Riede, B., Brdiczka, D.: Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for relation of permeability transition by the kinases. *Biochim Biophys Acta* 1998, 1368, 737-741.
9. Tsujimoto, Y.: Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria. *Genes Cells* 1998, 3, 697-707.